Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

No benefit of adding mannitol to cardiopulmonary bypass priming solution assessing cystatin C. A randomized clinical trial

Sköld, Andreas LU orcid ; Dardashti, Alain LU ; Lindstedt, Sandra LU and Hyllén, Snejana LU (2025) In Perfusion (United Kingdom)
Abstract

Introduction: There is no recommendation regarding the optimal prime solution for the cardiopulmonary bypass circuit in adult cardiac surgery. Despite the lack of scientific evidence, mannitol has frequently been added to the prime solution with intention to prevent acute kidney injury. The aim of this study was to investigate the impact of mannitol in cardiopulmonary bypass circuit prime in patients with preoperative renal dysfunction. Methods: This prospective, randomized, double-blind study included 70 patients, who underwent coronary artery bypass grafting. One group received 1200 mL of a prime based on Ringer’s acetate (n = 35), and the other a prime consisting of 1000 mL Ringer’s acetate and 200 mL mannitol (n = 35). Primary... (More)

Introduction: There is no recommendation regarding the optimal prime solution for the cardiopulmonary bypass circuit in adult cardiac surgery. Despite the lack of scientific evidence, mannitol has frequently been added to the prime solution with intention to prevent acute kidney injury. The aim of this study was to investigate the impact of mannitol in cardiopulmonary bypass circuit prime in patients with preoperative renal dysfunction. Methods: This prospective, randomized, double-blind study included 70 patients, who underwent coronary artery bypass grafting. One group received 1200 mL of a prime based on Ringer’s acetate (n = 35), and the other a prime consisting of 1000 mL Ringer’s acetate and 200 mL mannitol (n = 35). Primary endpoint were levels of Cystatin C, a renal function biomarker. Changes in renal-related parameters, electrolytes, osmolality and acid-base status were monitored. Results: The median cystatin C on day four in the mannitol group were 1.6 mg/L (IQR 1.4-2.0 mg/L) and 1,8 mg/L (IQR 1.5-2.1 mg/L) in the Ringer’s acetate group at the same time. Using mixed model analysis, no differences in cystatin C (p = 0.442), creatinine (p = 0.203), estimated glomerular filtration rate (p = 0.264) and urea (p = 0.141) could be detected between the groups. The mannitol group showed a more pronounced reduction in sodium levels after cardiopulmonary bypass circuit commencement compared to the Ringer’s acetate group p < 0.001. Conclusions: In patients with preoperative renal dysfunction, the addition of mannitol in the prime solution did not show any renoprotective effect measured by cystatin C compared to a cardiopulmonary bypass circuit prime based on Ringer's acetate. This study was reported to ClinicalTrials.org, id: NCT03302286. Effects of Extra Corporeal Circuit Prime on Electrolytes Balance and Clinical Outcome Following Cardiac Surgery https://clinicaltrials.gov/study/NCT03302286?id=NCT03302286&rank=1

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
in press
subject
keywords
CABG, cardiac surgery, cardiopulmonary bypass, cystatin C, mannitol, renal dysfunction
in
Perfusion (United Kingdom)
article number
02676591251344857
publisher
SAGE Publications
external identifiers
  • pmid:40411794
  • scopus:105008064587
ISSN
0267-6591
DOI
10.1177/02676591251344857
language
English
LU publication?
yes
additional info
Publisher Copyright: © The Author(s) 2025.
id
bfa55a2f-1268-4817-aad3-fc2eafc3e8a1
date added to LUP
2026-01-07 15:16:26
date last changed
2026-01-07 15:17:14
@article{bfa55a2f-1268-4817-aad3-fc2eafc3e8a1,
  abstract     = {{<p>Introduction: There is no recommendation regarding the optimal prime solution for the cardiopulmonary bypass circuit in adult cardiac surgery. Despite the lack of scientific evidence, mannitol has frequently been added to the prime solution with intention to prevent acute kidney injury. The aim of this study was to investigate the impact of mannitol in cardiopulmonary bypass circuit prime in patients with preoperative renal dysfunction. Methods: This prospective, randomized, double-blind study included 70 patients, who underwent coronary artery bypass grafting. One group received 1200 mL of a prime based on Ringer’s acetate (n = 35), and the other a prime consisting of 1000 mL Ringer’s acetate and 200 mL mannitol (n = 35). Primary endpoint were levels of Cystatin C, a renal function biomarker. Changes in renal-related parameters, electrolytes, osmolality and acid-base status were monitored. Results: The median cystatin C on day four in the mannitol group were 1.6 mg/L (IQR 1.4-2.0 mg/L) and 1,8 mg/L (IQR 1.5-2.1 mg/L) in the Ringer’s acetate group at the same time. Using mixed model analysis, no differences in cystatin C (p = 0.442), creatinine (p = 0.203), estimated glomerular filtration rate (p = 0.264) and urea (p = 0.141) could be detected between the groups. The mannitol group showed a more pronounced reduction in sodium levels after cardiopulmonary bypass circuit commencement compared to the Ringer’s acetate group p &lt; 0.001. Conclusions: In patients with preoperative renal dysfunction, the addition of mannitol in the prime solution did not show any renoprotective effect measured by cystatin C compared to a cardiopulmonary bypass circuit prime based on Ringer's acetate. This study was reported to ClinicalTrials.org, id: NCT03302286. Effects of Extra Corporeal Circuit Prime on Electrolytes Balance and Clinical Outcome Following Cardiac Surgery https://clinicaltrials.gov/study/NCT03302286?id=NCT03302286&amp;rank=1</p>}},
  author       = {{Sköld, Andreas and Dardashti, Alain and Lindstedt, Sandra and Hyllén, Snejana}},
  issn         = {{0267-6591}},
  keywords     = {{CABG; cardiac surgery; cardiopulmonary bypass; cystatin C; mannitol; renal dysfunction}},
  language     = {{eng}},
  publisher    = {{SAGE Publications}},
  series       = {{Perfusion (United Kingdom)}},
  title        = {{No benefit of adding mannitol to cardiopulmonary bypass priming solution assessing cystatin C. A randomized clinical trial}},
  url          = {{http://dx.doi.org/10.1177/02676591251344857}},
  doi          = {{10.1177/02676591251344857}},
  year         = {{2025}},
}